Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5706777 | 0.90 | ADORA2A (0.42) | ADORA2AADORA3ADORA2BADORA1CYP2C9 | |
| SCHEMBL258936 | 0.82 | LMNA (0.36) | ADORA2AADORA3ADORA1 | |
| SCHEMBL177666 | 0.78 | HSPA8 (0.44) | ADORA2AADORA3ADORA2BADORA1CYP1A2 | |
| SCHEMBL2295173 | 0.74 | ADORA2A (0.48) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL726188 | 0.72 | ADORA2A (0.46) | ADORA2AADORA3ADORA2BADORA1CYP1A2 | |
| SCHEMBL1081739 | 0.72 | ADORA2A (0.57) | ADORA2AADORA3ADORA2BADORA1CYP2D6 | |
| SCHEMBL940191 | 0.72 | ADORA2A (0.46) | ADORA2AADORA3ADORA2B | |
| Hydrochloric Acid SCHEMBL6754870 | 0.72 | ADORA2A (0.56) | ADORA2AADORA3ADORA2BADORA1CYP2D6 | |
| SCHEMBL7744270 | 0.72 | MAPK1 (0.40) | CYP1A2MAPK1 | |
| Hydrochloric Acid SCHEMBL2031973 | 0.71 | ADORA2A (0.55) | ADORA2AADORA3ADORA2BADORA1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | claimed |
| US-20210154177-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2021-05-27 | — | — | US | claimed |
| US-20210145803-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2021-05-20 | — | — | US | claimed |
| EP-3498297-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2019-06-19 | — | — | EP | claimed |
| US-20190134011-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2019-05-09 | — | — | US | claimed |
| US-20060205671-A1 | Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury | EMORY UNIVERSITY | 2006-09-14 | — | — | US | claimed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | disclosed |
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | disclosed |
| EP-3984555-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2022-04-20 | — | — | EP | disclosed |
| EP-3785733-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2022-01-05 | — | — | EP | disclosed |
| US-20210154177-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2021-05-27 | — | — | US | disclosed |
| US-20210145803-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2021-05-20 | — | — | US | disclosed |
| US-10940140-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2021-03-09 | — | — | US | disclosed |
| WO-2015041809-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20100272711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | THOMAS JEFFERSON UNIVERSITY (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100047798-A1 | ADENOSINE A1 AND A3 RECEPTOR GENE SEQUENCE VARIATIONS FOR PREDICTING DISEASE OUTCOME AND TREATMENT OUTCOME | THOMAS JEFFERSON UNIVERSITY (US) | 2010-02-25 | — | — | US | disclosed |
| US-20060205671-A1 | Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury | EMORY UNIVERSITY | 2006-09-14 | — | — | US | disclosed |
| US-6566371-B2 | Intraperitoneal administration of adenosine for the treatment of prevention of gastrointestinal of systemic diseases | UNIVERSITY OF PITTSBURGH | 2003-05-20 | — | — | US | disclosed |
| US-20020013290-A1 | Intraperitoneal administration of adenosine for the treatment or prevention of gastrointestinal or systemic diseases | PITTSBURGH, UNIVERSITY OF | 2002-01-31 | — | — | US | disclosed |
| WO-2001082934-A1 | INTRAPERITONEAL ADMINISTRATION OF ADENOSINE FOR THE TREATMENT OR PREVENTION OF GASTROINTESTINAL OR SYSTEMIC DISEASES | UNIVERSITY OF PITTSBURGH (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100047798-A1 | ADENOSINE A1 AND A3 RECEPTOR GENE SEQUENCE VARIATIONS FOR PREDICTING DISEASE OUTCOME AND TREATMENT OUTCOME | ADORA3, ADORA1, ADORA2A | ADORA2A 3/4885ADORA3 1/4885ADORA2B 4/4885 |
| US-20100272711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885ADORA3 4/4885ADORA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.